安罗替尼联合PD-1抑制剂治疗广泛期小细胞肺癌的疗效及安全性

doi:10.3969/j.issn.1006-5725.2023.17.017

Abstract

Abstract:

Objective To investigate the efficacy and safety of Anlotinib combined with PD-1 blockades in patients with extensive-stage small-cell lung cancer （ES-SCLC）. Methods This study retrospectively analyzed the data of 36 patients with ES-SCLC who were treated with at least one previous systematic chemotherapy regimen. All the patients received Anlotinib plus PD-1 blockades therapy. Results Efficacy evaluation and safety analysis were conducted in all the patients. The best efficacy results showed objective response rate was 27.8% （95%CI：14.2% ~ 45.2%）； disease control rate 80.6% （95%CI： 64.0% ~ 91.8%）. The PFS and OS of the 36 patients were 4.6 months （95%CI： 3.1 ~ 6.1） and 9.3 months （95%CI： 3.3 ~ 15.3）， respectively， indicating that overall adverse reactions were tolerate and controllable. Multivariate cox regression analysis for PFS indicated that ECOG performance status was the independent factor to predict PFS. Conclusion Anlotinib combined with PD-1 blockades regimen preliminarily demonstrates encouraging efficacy and tolerable safety for patients with ES-SCLC in real-world clinical practice.

Key words: small-cell lung cancer, anlotinib, PD-1 blockade, efficacy, safety

CLC Number:

R734.2

Jianguo LI,Shuman LI,Hui. CHEN. Efficacy and safety of Anlotinib combined with PD⁃1 blockades for extensive⁃stage small⁃cell lung cancer[J]. The Journal of Practical Medicine, 2023, 39(17): 2248-2252.

Figures/Tables 6

Fig.1

Fig.2

Fig.3

Tab.1

Tab.2

Tab.3

References 27

1	CALLES A， AGUADO G， SANDOVAL C， et al. The role of immunotherapy in small cell lung cancer［J］. Clin Transl Oncol， 2019， 21（8）： 961-976.
2	GUO H G， WEI J， LI X， et al. Do socioeconomic factors modify the effects of PM1 and SO2 on lung cancer incidence in China？［J］. Sci Total Environ， 2021， 756： 143998.
3	WANG Y W， ZOU S Y， ZHAO Z Y， et al. New insights into small-cell lung cancer development and therapy［J］. Cell Biol Int， 2020， 44（8）： 1564-1576.
4	熊艳，陈海文，牛玉春，等. 肺内和肺外小细胞癌基本临床特征的比较［J］. 实用医学杂志， 2023， 39（05）： 564-571.
5	MONTANINO A， MANZO A， CARILLIO G， et al. Angiogenesis Inhibitors in Small Cell Lung Cancer［J］. Front Oncol. 2021， 11： 655316.
6	CHENG Y， WANG Q M， LI K， et al. Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer： a randomised， double-blind， placebo-controlled Phase 2 study［J］. Br J Cancer， 2021， 125（3）： 366-371.
7	OGINO A， CHOI J， LIN M， et al. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations［J］. Mol Oncol， 2021， 15（1）： 27-42.
8	HORN L， MANSFIELD A S， SZCZESNA A， et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer［J］. N Engl J Med， 2018， 379（23）： 2220-2229.
9	PA L， DVORKIN M， CHEN Y B， et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer （CASPIAN）： a randomised， controlled， open-label， phase 3 trial［J］. Lancet， 2019， 394（10212）： 1929-1939.
10	LIM J U， KANG H S. A narrative review of current and potential prognostic biomarkers for immunotherapy in small-cell lung cancer［J］. Ann Transl Med， 2021， 9（9）：809.
11	SONG Y， FU Y， XIE Q， et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors： a promising strategy for cancer treatment ［J］. Front Immunol， 2020， 11： 1956.
12	FINN R S， QIN S， IKEDA M， et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma［J］. N Engl J Med， 2020， 382（20）： 1894-1905.
13	CHENG Y， WANG Q M， LI K， et al. OA13.03 anlotinib as third-line or further-line treatment in relapsed SCLC： a multicentre， randomized， double-blind phase 2 trial［J］. J Thorac Oncol， 2018， 13（10）： S351-S352.
14	MILLER T P， FISHER B T， GETZ K D， et al. Unintended consequences of evolution of the common terminology criteria for adverse events［J］. Pediatr Blood Cancer， 2019， 66（7）： e27747.
15	ANTONIA S J， LOPEZ-MARTIN J A， BENDELL J， et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer （CheckMate 032）： a multicentre， open-label， phase 1/2 trial［J］. Lancet Oncol， 2016， 17（7）： 883-895.
16	CHUNG H C， PIHA-PAUL S A， LOPEZ-MARTIN J， et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC： results from the KEYNOTE-028 and KEYNOTE-158 studies［J］. J Thorac Oncol， 2020， 15（4）： 618-627.
17	OTT P A， ELEZ E， HIRET S， et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer： results from the phase Ib KEYNOTE-028 study［J］. J Clin Oncol， 2017， 35（34）： 3823-3829.
18	HURWITZ J L， MCCOY F， SCULLIN P， et al. New advances in the second-line treatment of small cell lung cancer ［J］. Oncologist， 2009， 14（10）： 986-994.
19	TRIGO J， SUBBIAH V， BESSE B， et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer： a single-arm， open-label， phase 2 basket trial［J］. Lancet Oncol， 2020， 21（5）： 645-654.
20	SPIGEL D R， VICENTE D， CIULEANU T E， et al. Second-line nivolumab in relapsed small-cell lung cancer： Check Mate 331 ［J］. Ann Oncol， 2021， 32（5）： 631-641.
21	FAN Y， ZHAO J， WANG Q M， et al. Camrelizumab plus apatinib in extensive-stage SCLC （PASSION）： a multicenter， two-stage， phase 2 trial［J］. J Thorac Oncol， 2021， 16（2）： 299-309.
22	ASAO T， WATANABE S， TANAKA T， et al. A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer （ES-SCLC） patients with a poor performance status （PS）： NEJ045A study protocol ［J］. BMC Cancer， 2022， 22（1）： 1135.
23	RADES D， MOTISI L， VENINGA T， et al. Predictors of outcomes and a scoring system for estimating survival in patients treated with radiotherapy for metastatic spinal cord compression from small-cell lung cancer［J］. Clin Lung Cancer， 2019， 20（4）： 322-329.
24	ZHANG C G， YANG S， CHEN J H， et al. Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy ［J］. J Clin Oncol， 2021 39（）： 8568-8568.
25	MA S X， HE Z， WANG L L， et al. Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer： An objective performance trial ［J］. J Clin Oncol， 2022 40（）： 8568-8568.
26	WU D， NIE J， HU W H， et al. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer［J］. Int J Cancer， 2020， 147（12）： 3453-3460.
27	WANG F， QIN S K， SUN X C， et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab： data derived from a multicenter phase 2 trial［J］. J Hematol Oncol， 2020， 13（1）： 47.

临床病理特征	例数	mPFS （月）	95% CI	P值
ECOG PS 评分
0-1	17	5.6	4.31 ~ 6.89
2	19	3.8	2.68 ~ 4.92	0.021
一线治疗复发类型
铂敏感型	17	5.2	3.91 ~ 6.49
铂耐药型	19	3.8	2.73 ~ 4.87	0.041

特征	HR （95%CI）	df	P值
ECOG PS 评分
0 - 1 vs. 2	0.68 （0.37 ~ 0.91）	1	0.029
一线治疗复发类型
铂敏感型 vs. 铂耐药型	0.75 （0.49 ~ 1.05）	1	0.063

不良反应	例数	≥ 3级
高血压	19（52.8）	5（13.9）
疲劳	17（47.2）	2（5.6）
腹泻	14（38.9）	3（8.3）
手足综合征	14（38.9）	4（11.1）
皮肤毒性	12（33.3）	2（5.6）
贫血	9（25.0）	0（0.0）
ASL/ALT升高	7（19.4）	1（2.8）
蛋白尿	6（16.7）	1（2.8）
RCCEP	4（11.1）	0（0.0）
咯血	3（8.3）	0（0.0）
肺炎	3（8.3）	0（0.0）

[1]	Xi LIU,Xiaona LIU,Chao LI,Rui XIAN,Lihong CUI. Efficacy analysis of different regimens for treatment of Helicobacter pylori infection combined with small intestinal bacterial overgrowth [J]. The Journal of Practical Medicine, 2024, 40(9): 1303-1308.
[2]	Chao HAN,Xuemei ZHU,Ying WANG,Hui. SUN. Reflection on the standardized development of ambulatory medical care [J]. The Journal of Practical Medicine, 2024, 40(8): 1038-1041.
[3]	Yingyuan ZHANG,Chunyan MOU,Danqing XU,Yuanzhen WANG,Lixian CHANG,Chunyun LIU,Weikun LI,Hongyan WEI,Li LIU. Comparison of clinical efficacy of TMF and TDF in the treatment of hepatitis B liver fibrosis [J]. The Journal of Practical Medicine, 2024, 40(22): 3215-3220.
[4]	Yimei HUANG,Lulu ZHAO,Baotong. HUA. Application effect of insertable cardiac monitorin atrial fibrillation monitoring [J]. The Journal of Practical Medicine, 2024, 40(21): 3095-3100.
[5]	Fangmin GENG,Yuandan HE,Wenjuan LI,Qianqian LIU,Hongwei ZHANG,Zhangping LU,Lianhua WEI. Values of different DIC scoring systems in early diagnosis and prognosis prediction of coagulation dysfunction in sepsis patients [J]. The Journal of Practical Medicine, 2024, 40(2): 248-252.
[6]	Yanping WANG,Wenhui GAO,Yanting WU,Jun YANG,Yi ZHOU,Xiaoshun. JIAN. Analysis of influencing factors on clinical efficacy of neutropenia with febrile neutropenia in tumor patients [J]. The Journal of Practical Medicine, 2024, 40(18): 2597-2601.
[7]	Li CAI,Huichao CHEN,Yafei LI,Ding LUO,Jingwei CHEN,Honglian. OUYANG. Analyzing the prevention strategies of accidental puncture in traditional Chinese medicine acupuncture based on occupational exposure data [J]. The Journal of Practical Medicine, 2024, 40(18): 2635-2639.
[8]	Lei MENG,Jun SHANG,Yulong SUN,Yuxiang ZHANG,Meng HAN. Effect and prognosis of robot assisted percutaneous pedicle screw for thoracolumbar fracture [J]. The Journal of Practical Medicine, 2024, 40(12): 1696-1700.
[9]	ZHANG Tong, LI Xiaoyong, CHEN Yanjun, CHEN Shengyang, HU Shuiquan, CHENG Bingbing, TONG Hao, SONG Lishan.. Clinical efficacy of IRE ablation combined with PD ⁃1 inhibitor and chemotherapy in treatment of locally advanced pancreatic cancer [J]. The Journal of Practical Medicine, 2023, 39(9): 1153-1158.
[10]	HUANG Hancong, CHEN Qianhua, YANG Xiaorui.. Effects of cisplatin and pemetrexed combined with recombinant human endostatin injection in elderly patients with lung adenocarcinoma [J]. The Journal of Practical Medicine, 2023, 39(8): 1009-1014.
[11]	ZHANG Dandan, XU Feng, LI Ya, SONG Ruifeng, LIU Lin. . Efficacy and dose selection of glucocorticoid for severe drug ⁃induced liver injury [J]. The Journal of Practical Medicine, 2023, 39(6): 747-751.
[12]	WU Yang, LU Hanjie, SHUI Huifeng.. The efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung can⁃ cer previously treated with immunotherapy [J]. The Journal of Practical Medicine, 2023, 39(5): 572-578.
[13]	LI Yuanyuan, WANG Ce, DING Xiaochao, YU Xuezhu, LIU Jie, LIU Zhuowei.. The efficacy of mindfulness ⁃ based cognitive therapy combined with duloxetine for patients with somato⁃ form disorder [J]. The Journal of Practical Medicine, 2023, 39(5): 613-618.
[14]	Haitao TANG,Xian WANG,Tingxia CHAO,Fengmei WANG,Wenling JIA,Chunhui LIANG,Wenhua. ZHANG. Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients with decompensated cirrhosis [J]. The Journal of Practical Medicine, 2023, 39(24): 3249-3254.
[15]	Cheng LUO,Shengjie GUO,Zhiling ZHANG,Fangjian. ZHOU. Feasibility and safety analysis of domestic single-port robot system-assisted laparoscopic partial nephrectomy [J]. The Journal of Practical Medicine, 2023, 39(24): 3275-3280.

Efficacy and safety of Anlotinib combined with PD⁃1 blockades for extensive⁃stage small⁃cell lung cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 27

Related Articles 15

Recommended Articles

Metrics

Comments